June 2025 in “The Journal of Dermatology” Baricitinib is effective and safe for long-term treatment of severe alopecia areata.
April 2025 in “Digital Commons - East Tennessee State University (East Tennessee State University)” Long COVID can cause lasting health issues like fatigue and brain fog, especially in those with severe initial infections or no vaccination.
April 2025 in “The Journal of Urology” Long-term finasteride use may lower prostate cancer risk but increase the need for erectile dysfunction medication.
March 2025 in “Daehan saengsik uihak hoeji/Clinical and experimental reproductive medicine” Long-term use of dutasteride for hair loss may harm semen quality.
February 2025 in “JOURNAL OF COMMUNICABLE DISEASES” Many COVID-19 survivors still face health issues months later, so ongoing medical support is important.
January 2025 in “British Journal of Dermatology” Long scalp hair evolved for cooling and social signaling.
January 2025 in “BMC Genomics” Long non-coding RNAs help regulate wool fineness in Gansu alpine fine-wool sheep.
November 2024 in “The Medical Journal of Australia” Long COVID has severely affected a couple's health, finances, and social life.
October 2024 in “The Journal of Dermatology” Intravenous corticosteroid therapy is effective for long-term hair regrowth in alopecia areata, and a scoring system helps predict treatment success and relapse.
October 2024 in “Journal of Neuroscience Research” Long-term Finasteride treatment reduces depression better than short-term treatment in rats.
A new method allows detailed tracking of cell regeneration in crustacean legs.
August 2024 in “Current Issues in Molecular Biology” Key genes and RNAs related to hair growth in sheep were identified, aiding future breeding improvements.
August 2024 in “Skin Appendage Disorders” Long-term use of high-dose topical minoxidil can cause thickened, ridged scalp.
July 2024 in “Behavioural Brain Research” Long-term finasteride treatment reduces depression and brain issues in obese male rats.
July 2024 in “Influenza and Other Respiratory Viruses” Analyzing both TE and AA together is crucial for understanding post-COVID-19 hair loss.
June 2024 in “Journal of Dermatology & Cosmetology” The FUL hair restoration technique is better for aesthetics and causes less scarring.
April 2024 in “Public health” Vaccination and timely treatment reduce the risk of long COVID.
February 2024 in “Curēus” Long COVID is more common in those with severe initial infections, but not linked to blood group.
February 2024 in “The Journal of Dermatology” Dutasteride 0.5 mg is safe and effective for long-term use in Korean men with hair loss.
January 2024 in “Diagnostics” Long COVID causes a wide range of long-lasting symptoms that change over time and are hard to diagnose and treat.
January 2024 in “Annals of Agricultural and Environmental Medicine” Red LED light therapy helps reduce hair loss and improves hair regrowth in long COVID patients.
January 2024 in “International Journal of Dermatology Sciences” Microneedling with CGF significantly improves hair regrowth in androgenetic alopecia.
January 2024 in “Pediatria Polska” Long-COVID symptoms in children after MIS-C are similar across different COVID-19 variants, with older age being a key factor.
December 2023 in “Malahayati International Journal of Nursing and Health Science” Chemotherapy in children often causes hair loss, nausea, vomiting, and mood swings.
September 2023 in “medRxiv (Cold Spring Harbor Laboratory)” Long-COVID has diverse, long-term health impacts, especially in young people.
August 2023 in “Journal of Dermatological Science” A specific RNA molecule blocks hair growth by affecting a protein related to hair loss conditions.
The RNA AL136131.3 slows down hair growth and speeds up hair loss by affecting sugar breakdown in hair follicles.
April 2023 in “Journal of Investigative Dermatology” Long-term Imiquimod treatment causes initial skin inflammation that lessens over time, and topical corticosteroids reduce this inflammation and cytokines in a mouse model of psoriasis.
IVL-DrugFluidic® can mass-produce high-quality, long-acting injectable drug microspheres, improving patient compliance and reducing side effects.
The study concludes that long COVID recovery involves time, various treatments, and a strong patient-provider relationship.